SCHEMBL6958899

SCHEMBL6958899

ClCCCN1c2cc(Cl)ccc2CCc2ccc(Cl)cc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.59
TP53 P04637 3/20 0.59
CYP3A4 P08684 3/20 0.59
HTR2C P28335 3/20 0.59
HTR2B P41595 3/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
SLC22A1 O15245 2/20 0.59
ABCB11 O95342 2/20 0.59
CYP1A2 P05177 2/20 0.59
CHRM2 P08172 2/20 0.59
CHRM4 P08173 2/20 0.59
ADRB1 P08588 2/20 0.59
HTR1A P08908 2/20 0.59
CHRM5 P08912 2/20 0.59
ADRA2A P08913 2/20 0.59
ADORA3 P0DMS8 2/20 0.59
CYP2D6 P10635 2/20 0.59
CHRM1 P11229 2/20 0.59
DRD2 P14416 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6963908 0.92 HTR2A (0.71) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL29485936 0.79 HTR2A (0.74) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL14707047 0.79 HTR2A (0.74) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL8195707 0.79 HTR2A (0.70) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL29485897 0.77 HTR2A (0.68) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL22748895 0.77 HTR2A (0.68) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL7168599 0.77 HTR2A (0.68) HTR2ATP53CYP3A4HTR2CHTR2B
Hydrochloric Acid SCHEMBL14698744 0.77 HTR2A (0.72) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL3749292 0.77 HTR2A (0.68) HTR2ATP53CYP3A4HTR2CHTR2B
SCHEMBL22767581 0.76 HTR2A (0.67) HTR2ATP53CYP3A4HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613791-B1 Treating migraine, neurogenic inflammation, rheumatoid arthritis or insulin resistance NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-0820451-B1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK AS (DK) 2003-01-15 EP disclosed
US-6239148-B1 TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, NOVO NORDISK A/S (DK) 2001-05-29 US disclosed
US-6166009-A N-substituted azaheterocyclic carboxylic acids and esters thereof NOVO NORDISK A/S (DK) 2000-12-26 US disclosed
US-6110913-A ANTIINFLAMMATORY AGENTS, ANALGESICS NOVO NORDISK A/S (DK) 2000-08-29 US disclosed
US-6071901-A TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES NOVO NORDISK A/S (DK) 2000-06-06 US disclosed
EP-0820451-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1998-01-28 EP disclosed
WO-1996031498-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1996-10-10 WO disclosed